Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside
Black Diamond Therapeutics trades below cash value, offering a compelling risk/reward profile in precision oncology. Silevertinib, BDTX's lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR, targeting NSCLC patients underserved by legacy TKIs. Despite mega-cap competition, BDTX's $118M cash runway, potential non-dilutive milestone payments, and MasterKey platform underpin a Buy rating.
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset.
BDTX Shares Gain 11% in a Week: Here's What You Should Know
Black Diamond stock rises after its Q1 results reflect lower costs, a cash runway into 2028 and continued progress for lead candidate silevertinib.
Implied Volatility Surging for Black Diamond Therapeutics Stock Options
Investors need to pay close attention to BDTX stock based on the movements in the options market lately.
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right
Black Diamond Therapeutics hinges on silevertinib, with 2026 data on progression-free survival and durability set to determine whether its single-asset story can justify upside.
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize
Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung cancer market.
Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks
BDTX rides on silevertinib, with 2026 durability data set to test early NSCLC efficacy and CNS signals, making upcoming readouts a decisive swing factor.
Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?
Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock?
BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026
BDTX spotlights silevertinib's 86% CNS response in NSCLC, with 2026 durability data and a glioblastoma push shaping its brain-metastasis strategy.
